
The official advocacy organization for pharmacist women in the United States
Pharmacist Moms Group™

45,000+ Members

Over 6 Million posts, comments and reactions in 2020

60,000+ Followers on social media platforms
The Largest Community of Women Pharmacists in the US

Founded in 2017, Pharmacists Moms Group was created to provide women pharmacists the opportunity to network, collaborate and offer genuine feedback in a closed-door, trusted setting. The organization has quickly grown to over 45,000 members and 60,000 followers on our social media platforms.

While we may not be able to control what happens to us, we can ALWAYS control how we respond. Working on self-awareness and self-improvement will certainly create positive habits to help you when you are stuck.

Read on to learn more about Jennifer’s path to pharmacy ownership, and to learn how COVID-19 and the Oregon wildfires have impacted her business.

Miss America 2020, Camille Schrier, has been a proud, self-described “science nerd” for as long as she can remember. We caught up with Camille to get a student’s perspective on the future of the profession.

Time-to-vaccination data from a large diabetes cohort reveal delayed, incomplete uptake of pneumococcal vaccination, with age and citizenship emerging as the strongest predictors.

The phase 3 findings support MR-107A-02's potential as a nonopioid option for certain patients with moderate to severe acute pain.

Five "essential" outcomes, including medication error and adherence, should anchor every pharmacist intervention study in chronic kidney disease.

Melissa Seifert, PharmD of UPMC Health Plan explains how managed care pharmacists guide DMT selection and address adherence barriers in patients with MS.

A clinical pharmacy specialist at UPMC Health Plan discusses how pharmacists help select disease-modifying therapies, address adherence barriers, and coordinate whole-person care for those with MS.

In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial, discusses why intravenous arginine did not shorten time to crisis resolution and how institutional variation, pain heterogeneity, shorter hospital stays, and treatment timing may have influenced the findings.






.png)



